The Volkswagen Robotaxi That Wants to Rival Waymo and Tesla
'Not the best driving decision,' sighed Christian Senger, head of autonomous vehicles at Volkswagen VOW3 -1.19%decrease; red down pointing triangle, which built the robotaxi.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
34 minutes ago
- Bloomberg
Germany's $40 Billion Pension Gives Mandate to China Stock Fund
A German pension fund has tapped a Chinese firm's Hong Kong arm to help it invest in local stocks, in a rare move among global allocators that have been cautious about gaining exposure to the nation's equities. KZVK, which manages €34.1 billion ($40 billion), gave $50 million to Fullgoal Asset Management (HK) Ltd. in the second quarter, according to people with knowledge of the matter. The mandate is to invest in Chinese equities listed in Hong Kong, the mainland and the US, the people said, asking not to be identified as the information is private.
Yahoo
34 minutes ago
- Yahoo
BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M
BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is one of the best high short interest stocks with huge upside potential. On June 27, BioCryst Pharmaceuticals announced a definitive agreement to sell its European ORLADEYO (berotralstat) business to Neopharmed Gentili for a total consideration of up to $264 million. The amount includes an upfront payment of $250 million for the European assets and rights related to ORLADEYO, along with up to an additional $14 million in future milestones contingent on sales in Central and Eastern Europe. The closing of this transaction is anticipated by early October this year. BioCryst plans to utilize the proceeds from this sale to retire all remaining term debt, amounting to $249 million from Pharmakon. A scientist in a lab coat observing a line of medicine pills in a container. This is expected to eliminate ~$70 million in future interest payments over the remaining life of the loan. Consequently, BioCryst projects to end 2027 with ~$700 million in cash and no term debt, representing an increase of $400 million compared to its previous net cash guidance for 2027. The acquisition by Neopharmed Gentili also involves taking over BioCryst's European organization, which is expected to result in at least $50 million in annual operating expense savings for BioCryst. BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is a biotechnology company that develops oral small-molecule and injectable protein therapeutics to treat rare diseases. Neopharmed Gentili is a pharmaceutical company founded in Italy. While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Bloomberg
an hour ago
- Bloomberg
Italy's Bridge to Nowhere Shows Defense-Boom Risks
The defense boom in Europe is as close to a tech-style gold rush as the Old Continent can offer. Armaments stocks are outperforming Nvidia Corp., and defense-themed funds are amassing billions in anticipation of rising military spending in a more dangerous world. NATO allies have agreed to more than double defense spending goals to 5% of gross domestic product in the coming years. But with so many countries already struggling to stump up the billions needed to keep up in artificial intelligence, reindustrialization and the energy transition, where's the cash going to come from? With the notable exception of Germany, many European countries are already near the limit of investor and voter patience with borrowing and taxation. And good luck shrinking the welfare state.
